Psychiatry Research
February 2, 2026
Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al.
1 citation
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...
Psychology International
December 19, 2025
Morgan C H Cheng, Tatiana Aboulafia Brakha, Albert Buchard et al.
Classic psychedelics such as lysergic acid diethylamide (LSD) and psilocybin induce mild cardiovascular activation in addition to their psychological effects. While these effects are well described in healthy adults, little is known about their dynamics in clinical populations undergoing psychedelic-assisted psychotherapy. This retrospective, observational, single-center study analyzed...
Research Square
December 1, 2025
Albert Buchard, Federico Seragnoli, Michel Sabé et al.
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with baseline depression and anxiety. This study characterized EMS in 192 adults and longitudinally followed 74 patients receiving psilocybin- or LSD-assisted therapy. We found that baseline schema burden, particularly related to failure and defectiveness,...
Psychoactives
September 1, 2025
M Mercier, Cédric Mabilais, Vasileios Chytas et al.
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatment of psychiatric disorders such as depression and anxiety. While evidence regarding their role in chronic pain management remains limited, emerging studies suggest potential therapeutic benefits. This case report describes a patient with persistent...
Psychoactives
August 1, 2025
L. Cazorla, Sylvie Alaux, Caroline Amberger et al.
Despite growing evidence supporting the efficacy of LSD-assisted psychotherapy in treating major depressive disorder (MDD), identifying reliable psychopharmacological biomarkers remains necessary. Oxytocin, a neuropeptide implicated in social bonding and flexibility, is a promising candidate due to its release following serotonergic psychedelic administration in healthy individuals; however,...
J Psychiatry Neurosci
July 25, 2025
Michel Sabé, Federico Seragnoli, Gabriel Thorens et al.
2 citations
Treatment of depressive and negative symptoms in individuals with schizoaffective disorders using serotoninergic psychedelics: a case report.
European Psychiatry
April 1, 2025
L. Cazorla, Sylvie Alaux, Cédric Mabilais et al.
Introduction One of the main mechanisms of action of LSD in psychedelic-assisted psychotherapy (PAP) is the activation of 5HT2A receptors. This triggers a cascade of neurochemical processes with the release of neurotransmitters and neurohormonal substances. The release of oxytocin in this process is well documented in pre-clinical studies, with recent evidence in healthy subjects. We have no...
Cognitive Therapy and Research
March 29, 2025
Federico Seragnoli, Fabienne Picard, Gabriel Thorens et al.
4 citations
Abstract Purpose Despite the presence of mystical-type experiences in psychedelic-assisted therapy (PAT), an understanding of the cognitive processes involved is still lacking. Guided by theory and empirical research, we hypothesized a cognitive-grounded perspective based on current metacognition models to promote the understanding of the psychological processes involved in mystical-type...
Molecular Psychiatry
March 1, 2025
Michel Sabé, Adi Sulstarova, Alban Glangetas et al.
39 citations
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders. We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of...
European Psychiatry
August 27, 2024
Daniele Zullino, Louise Penzenstadler, Stéphane Rothen et al.
Introduction While research on drug use motives has primarily focused on widely used substances like alcohol, tobacco, and cannabis, understanding the motivations behind MDMA use is crucial for developing targeted therapeutic, preventive, and harm reduction strategies. Objectives The objective of this study is to present the findings of an online survey that evaluates the motives behind the use...
Annales Médico-psychologiques revue psychiatrique
July 10, 2024
Federico Seragnoli, Gabriel Thorens, Louise Penzenstadler et al.
8 citations
Dans cet article, nous avons pour objectif de décrire un modèle interdisciplinaire de psychothérapie assistée par psychédéliques (PAP) que nous avons développé dans un cadre institutionnel aux hôpitaux universitaires de Genève. La psychothérapie assistée par psychédéliques (PAP) est une approche psychothérapeutique exploitant l’altération de l’état de conscience induite par une substance...
Revue medicale suisse
February 14, 2024
Aude Molinard-Chenu, Georgios Tsimploulis, Louise Penzenstadler et al.
Psychedelics are emerging as a therapeutic innovation in psychiatry and their use in chronic pain is worth exploring. In fact, they can modulate the serotonergic system, affecting central pain sensitization mechanisms. Ketamine, used for chronic analgesia, can lead to pain reduction, but additional studies are needed to assess its longterm effectiveness. "Classic" psychedelics are recently...
Revue medicale suisse
August 23, 2023
Gabriel Thorens, Louise Penzenstadler, Federico Seragnoli et al.
2 citations
This article proposes 10 points considered essential on the ethics associated with the practice of psychotherapy assisted by psychedelics (PAP) : 1) respect of the legal framework (LStup) of the use of psychotropic drugs ; 2) adequately manage psychedelics (storage, production and safety) ; 3) announce adverse effects to the competent authority ; 4) guarantee a psychotherapeutic follow-up ; 5)...
European Neuropsychopharmacology
August 7, 2023
Natacha Perez, Florent Langlest, Luc Mallet et al.
85 citations
Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...
Research Square (Research Square)
May 12, 2023
Gabriel Thorens, Louise Penzenstadler, Leonice Furtado et al.
Abstract Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient had failed to respond to conventional psychotherapeutic treatment. After three sessions of psilocybin-assisted psychotherapy, the patient experienced a reduction in anxiety and fear associated with closed spaces, elevators, and planes. The protocol...
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
November 1, 2022
Marco Solmi, Chaomei Chen, Charles Dauré et al.
55 citations
A scientometric analysis was realized to outline clinical research on psychedelics over the last century. Web of Science Core Collection was searched up to March 18, 2022, for publications on psychedelics. Network analyses and bibliometrics were combined, to identify research themes and trends with Bibliometrix and CiteSpace. The primary aim was to measure research trends evolution over time,...